Landiolol given early to people having a heart attack with ST elevation
Tests landiolol, given early, in adults with ST-elevation heart attack needing a procedure.
Key facts
- Who runs it
- Medical University Of Vienna
- Where
- Vienna, AustriaSee the site
- Trial code
- Registry title
- The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention – A prospective, randomized, double-blinded, placebo-controlled, phase IV pilot trial (STEMILAND-1)
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 60 people, planned
- Started
- 7 Jan 2026
- Expected to end
- 1 Jun 2027
- Type of study
- Interventional
- Record updated
- 16 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a heart attack of the front or side wall of the heart (ST-elevation acute coronary syndrome) who are treated at the study center. They must be stable and have a heart rate above 70 per minute.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Anterior or lateral ST-elevation acute coronary syndrome, with ST-segment elevation in two or more of the chest leads V1-V6, and I and aVL. Hemodynamically stable (MAP >60 mmHg, heart rate > 70/min).
Main reasons for not taking part
- Known or suspected pregnancy
- Acute asthma exacerbation
- Acute heart failure or cardiogenic shock (Killip Classes III and IV)
- Known problems of the heart's electrical conduction system (e.g., sick-sinus-syndrome, AV-block II° or III°)
- Allergy or insensitivity to ß-blockers
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Anterior or lateral ST-elevation acute coronary syndrome (STE-ACS; defined as ST-segment elevation in two or more of precordial leads V1-V6, and I and aVL, representing anterior wall infarction or ischemia)
- Treated at our study center
- Age >= 18 years
- Hemodynamically stable (MAP >60 mmHg, heart rate > 70/min)
- Oral and written informed consent
Who cannot take part
- Known pathologies of the cardiac electrical conduction system (e.g., sick-sinus-syndrome, AV-block II° or III°)
- Acute heart failure and cardiogenic Shock (Killip Classes III and IV)
- Allergy or insensitivity to ß-blockers
- Known pulmonary hypertension
- Heart rate < 50 bpm
- Known or suspected pregnancy
- Acute asthma exacerbation
- Severe metabolic acidosis
- Known pheochromocytoma
- Anticipated time to wire-crossing >120 minutes after first medical contact
- Thrombolysis candidate as defined by treating physician
Where in Austria
- Klinik LandstrasseVienna, AustriaNot yet recruiting
About the trial
What the trial wants to find out
The primary objective is to evaluate the feasibility of very early continuous i.v. administration of the highly cardioselective betablocker Landiolol in anterior/lateral ST-elevation acute coronary syndrome (STE-ACS).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention – A prospective, randomized, double- blinded, placebo controlled, phase IV pilot trial (STEMILAND-1)
- Plain-language title
- Landiolol given early to people having a heart attack with ST elevationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 16 September 2026